PMID- 31880339
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1651-2227 (Electronic)
IS  - 0803-5253 (Linking)
VI  - 109
IP  - 9
DP  - 2020 Sep
TI  - A single centre experience of treatment outcomes for Helicobacter pylori 
      infection among inner-city children and adolescents.
PG  - 1860-1866
LID - 10.1111/apa.15150 [doi]
AB  - AIM: This study assessed treatment outcomes of Helicobacter pylori (H pylori) 
      infection among inner-city children. METHODS: This was a retrospective study of 
      patients aged 1-21 years who underwent initial treatment for H pylori infection 
      from 2011 to 2015. We included patients who completed 2 weeks of treatment with 
      documented adequate compliance after H pylori infection was diagnosed. Treatment 
      outcomes were measured based on stool H pylori antigen and/or histology. RESULTS: 
      Of the total 261 patients diagnosed with H pylori, 239 completed the first-line 
      treatment. The regimens used included amoxicillin/clarithromycin/proton pump 
      inhibitor (PPI) in 207/239 patients (86.6%), amoxicillin/metronidazole/PPI in 
      14/239 patients (5.8%) and other regimens in 18/239 patients (7.5%). H pylori 
      eradication status was tested in 111/207 (53.6%) patients treated with 
      amoxicillin/clarithromycin/PPI, and the eradication was achieved in 84/111(75.7%) 
      patients. The treatment success rates for amoxicillin/metronidazole/PPI and other 
      regimens were 71.4% (5/7) and 63.6% (7/11), respectively. There was no 
      statistical significance of post-treatment stool H pylori antigen results between 
      PPI (n = 31) and no PPI (n = 43) users. CONCLUSION: The study showed an 
      eradication rate of 75.7% with the regimen amoxicillin/clarithromycin/PPI 
      suggesting significant antibiotic resistance in our population. The use of PPI 
      did not influence post-treatment stool H pylori antigen results.
CI  - (c) 2019 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
FAU - Mathews, Jubin
AU  - Mathews J
AD  - Division of Pediatric Gastroenterology, Hepatology and Nutrition, The Children's 
      Hospital at Montefiore, Bronx, New York.
FAU - Malik, Preeti
AU  - Malik P
AUID- ORCID: 0000-0002-9427-0225
AD  - Division of Pediatric Gastroenterology, Hepatology and Nutrition, The Children's 
      Hospital at Montefiore, Bronx, New York.
FAU - Rai, Anjali
AU  - Rai A
AD  - The Children's Hospital at Montefiore, Bronx, New York.
FAU - Lin, Juan
AU  - Lin J
AD  - Albert Einstein College of Medicine, Bronx, New York.
FAU - Kim, Ryung S
AU  - Kim RS
AD  - Albert Einstein College of Medicine, Bronx, New York.
FAU - Pan, Debra H
AU  - Pan DH
AUID- ORCID: 0000-0002-4418-437X
AD  - Division of Pediatric Gastroenterology, Hepatology and Nutrition, The Children's 
      Hospital at Montefiore, Bronx, New York.
LA  - eng
PT  - Journal Article
DEP - 20200226
PL  - Norway
TA  - Acta Paediatr
JT  - Acta paediatrica (Oslo, Norway : 1992)
JID - 9205968
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Drug Therapy, Combination
MH  - *Helicobacter Infections/drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Infant
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Helicobacter pylori infection
OT  - children
OT  - treatment outcome
EDAT- 2019/12/28 06:00
MHDA- 2021/05/15 06:00
CRDT- 2019/12/28 06:00
PHST- 2019/04/01 00:00 [received]
PHST- 2019/12/16 00:00 [revised]
PHST- 2019/12/23 00:00 [accepted]
PHST- 2019/12/28 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2019/12/28 06:00 [entrez]
AID - 10.1111/apa.15150 [doi]
PST - ppublish
SO  - Acta Paediatr. 2020 Sep;109(9):1860-1866. doi: 10.1111/apa.15150. Epub 2020 Feb 
      26.